Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tipifarnib

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Tipifarnib. Displaying page 1 of 1.
    EudraCT Number: 2004-001719-77 Sponsor Protocol Number: R115777-AML-301 Start Date*: 2004-10-22
    Sponsor Name:Johnson & Johnson Pharmaceutical Research and Development
    Full Title: A Randomized Study of Tipifarnib Versus Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Subjects 70 Years or older.
    Medical condition: Treatment of Acute Myeloid Leukemia (AML)
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SE (Completed) DK (Completed) IE (Completed) DE (Completed) ES (Completed) SK (Completed) IT (Completed) GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-001437-40 Sponsor Protocol Number: KO-TIP-007 Start Date*: 2019-03-08
    Sponsor Name:Kura Oncology, Inc.
    Full Title: The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM...
    Medical condition: Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063569 Metastatic squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) GB (GB - no longer in EU/EEA) NO (Completed) BE (Completed) AT (Completed) NL (Completed) GR (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004822-13 Sponsor Protocol Number: GECP17/04 Start Date*: 2018-05-23
    Sponsor Name:Spanish Lung Cancer Group (SLCG/GECP)
    Full Title: An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer with HRAS mutations
    Medical condition: squamous non-small cell lung cancer (SQ-NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025044 Lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-001396-69 Sponsor Protocol Number: KO-TIP-002 Start Date*: 2016-10-27
    Sponsor Name:Kura Oncology Inc.,
    Full Title: An Open Label Phase II Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell LymphomaLymphoma
    Medical condition: Subjects with Relapses and Refractory Peripheral T-Cell Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-004535-12 Sponsor Protocol Number: KO-TIP-001 Start Date*: 2016-02-25
    Sponsor Name:Kura Oncology, Inc.
    Full Title: An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies with HRAS Mutations
    Medical condition: Advanced Non-Hematological Malignancies with HRAS mutations
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048683 Advanced cancer LLT
    18.1 10018065 - General disorders and administration site conditions 10071971 H-ras gene mutation PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-007066-11 Sponsor Protocol Number: MCL06-1 Start Date*: 2007-05-02
    Sponsor Name:GELA
    Full Title: A phase II study evaluating the efficacy and safety of the farnesyltransferase inhibitor ZARNESTRA® (R115777, tipifarnib) in patients with relapsed , refractory or progressive mantle cell lymphoma ...
    Medical condition: adult patients with relapsed , refractory or progressive mantle cell lymphoma not appropriate for autologous bone marrow transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10026800 Mantle cell lymphoma recurrent LLT
    9.1 10026801 Mantle cell lymphoma refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000273-35 Sponsor Protocol Number: 2/2007/U/Sper Start Date*: 2007-03-22
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: A Phase II, Open-Label, Multi-centre, 2-part study to assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Newly Diagnosed Acute Myeloid Leukemia AML ...
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    6.1 10024291 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001563-36 Sponsor Protocol Number: CRAD001MIL04T Start Date*: 2016-05-12
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: A Phase II Study of RAD001 in the Treatment of Patients With Plexiform Neurofibromas (PN) Associated With Neurofibromatosis Type 1 (NF1)
    Medical condition: Plexiform Neurofibroma Associated With Neurofibromatosis Type 1
    Disease:
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-002847-14 Sponsor Protocol Number: CU 106 Start Date*: 2005-12-16
    Sponsor Name:Cardiff University
    Full Title: AML16; A National Cancer Research Institute Trial in Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndromes
    Medical condition: Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    7.1 10000880 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 19:35:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA